EP12.01. Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Shencun Fang
Meta Tag
Speaker Shencun Fang
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
metastatic non-small cell lung cancer
EGFR co-mutations
first-line therapy
retrospective study
objective response rate
disease control rate
progression-free survival
overall survival
Powered By